The green dye from the indocyanine green (ICG) injection gathers around the...
The green dye from the indocyanine green (ICG) injection gathers around the sarcoma under the skin

Image source: Newcastle University

News • Fluorescence lifetime imaging

New technique for distinguishing tumour from normal tissue

Removing a patient’s tumour while sparing healthy tissue requires precision, but often surgeons must rely on their eyes and hands to determine where to cut.

A team of researchers has developed a visualisation tool that combines high-speed cameras and fluorescent injection to distinguish tumour tissue from normal tissue across cancer types. The experts evaluated the new imaging technology, known as fluorescence lifetime (FLT) imaging, using specimens from more than 60 patients, including those from Newcastle Hospitals, who underwent surgery of various cancers. 

In a paper, published in Nature Biomedical Engineering, the team reported that the technique was over 97% accurate across tumour types, with the potential to improve the accuracy of cancer surgeries.

Many technologies have been pursued to improve visualization of tumours during surgery, including fluorescence imaging and advanced microscopy, but such technologies have not yet been widely adopted and most are restricted to specific types or subtypes of cancer. Fluorescence imaging can use dyes to target cancer-specific molecules, but standard imaging techniques can have limited accuracy for detecting tumour margins—or the edges of normal tissue that surround a tumour—since the expression of these molecules can vary widely within and across tumour types. 

The technique used by the team, known as FLT imaging, takes a different tact. Instead of relying on dyes only for targeting cancer, the technique uses high-speed cameras to detect changes in the property of the light emitted by tissue. In their current study, experts applied the same principle to samples from patients. The team began by analysing samples from patients undergoing liver, head and neck surgery. Patients had received an ICG injection at least a day before the surgery. Building on this initial work, the team collaborated across multiple institutions and evaluated specimens from more than 60 patients representing multiple cancer types, including liver, brain, tongue, skin, bone and soft tissue. 

The team was able to detect an FLT shift at the cellular level that was consistent across tumour types and in multiple patients. The technique was also able to distinguish benign from metastatic lymph nodes. Overall, it was more than 97% accurate at distinguishing tumour tissue from healthy tissue.

portrait of kenneth rankin
Dr Kenny Rankin

Image source: Newcastle University 

Dr Kenny Rankin, Honorary Senior Lecturer at Newcastle University and Consultant Orthopaedic Surgeon at Newcastle Hospitals, said: “On behalf of the North of England Bone and Soft Tissue Tumour Service it has been exciting to work on this project. 

“Our contribution has included input from patients undergoing surgery for musculoskeletal cancers who kindly donated their tumours for research and also the NovoPath laboratories who were able to support the processing of the tissue. We look forward to the next developments which will put Newcastle at the forefront of the introduction of this technology into clinical practice.” 

Source: Newscastle University


Read all latest stories

Related articles


News • BPE in dense breasts

Breast cancer: elevated MRI enhancement identifies higher risk

A machine learning model found that background parenchymal enhancement (BPE) on breast MRI is an indicator of breast cancer risk in women with extremely dense breasts.


News • Precision oncology

Genomic sequencing benefits only 5% of cancer patients

Genomic sequencing panels as part of personalised cancer treatment have been found to only benefit one in 20 patients they are currently used for, according to a study by CNIO.


News • Conveying probability

“You (might) have cancer” – Pitfalls in doctor-patient communication

A new study from Munich reveals: Whether patients are able to correctly assess risks depends partly on how physicians convey statistical information to them.

Related products

teamplay Images

Portal Solutions

Siemens Healthineers · teamplay Images

Siemens Healthcare GmbH
Subscribe to Newsletter